Rodman & Renshaw Capital Group, Inc. (NASDAQ: RODM), today announced that Michael G. King, Jr. has been named Head of Healthcare, a newly created role at the firm. King was formerly Director of Research at Rodman. Rodman also announced that Christopher James, MD, formerly a Senior Associate Analyst working for King, has rejoined the firm and will assume research coverage of many of King’s stocks.
Rodman announced the move as part of its ongoing efforts to ensure that key personnel are deployed as much as possible in client-facing and revenue-enhancing activities. In his new position, Mr. King will draw upon the relationships that he has developed with a wide range of healthcare companies, as well as the physician opinion leaders and buy-side clients he has dealt with over the years. Mr. King will leverage these relationships to provide integrated advice on financings, partnerships and strategic transactions, including mergers, acquisitions, divestitures and strategic restructurings. King will also continue to contribute to Rodman’s knowledge leadership in healthcare by writing industry thought pieces, white papers, and general commentary on the trends in the biotechnology/life science space.
“As our business grows and our clients’ needs evolve, we believe that it is in the best interests of our clients and our franchise to have Mike’s ample talents and experience available in creative new ways,” said Michael Lacovara, Rodman’s CEO. “Mike’s new role as Head of Healthcare is a huge win for Rodman, our clients, and for Mike. We are also delighted to have Chris James rejoin our team. Chris will ensure continuity of research coverage of Mike’s stocks and embodies our continued commitment to Rodman’s distinguished healthcare research.”
“I am thrilled with my new role at Rodman, and have enjoyed my tenure as an analyst and Rodman’s Director of Research. I look forward to using my 15 years of experience as an analyst to provide valuable advice to the companies in our industry,” said Michael G. King, Jr, Rodman’s Head of Healthcare. “Now, more than ever, biotechnology companies need advice that is based on a complete understanding of the company’s life cycle and prevailing market dynamics. The environment we face is the most challenging ever, and the capital markets have been forever changed. I hope to bring my expertise as a key player in the market to bear on how companies run and finance their businesses.”
Michael King joined Rodman & Renshaw in May of 2005 as a Senior Biotechnology Analyst and has covered companies across a wide spectrum of market capitalizations and therapeutic categories. Prior to joining Rodman, Mr. King was a Managing Director and Senior Equity Research Analyst in the Health Care Group at Banc of America Securities LLC, where he covered the biotechnology sector. Mr. King joined Banc of America Securities LLC, in 2002 from Robertson Stephens, where he had been a Managing Director and Senior Biotechnology Analyst since 1998. Prior to that, he served as senior biotechnology analyst at Vector Securities from 1996 to 1998 and at Dillon, Read & Co. from 1994 to 1996. He has also held positions at D. Blech & Company, Alex Brown and Sons, Hambrecht & Quist and Kidder, Peabody & Company. He earned a BBA with honors in finance from Baruch College.
Christopher James, MD, is rejoining Rodman & Renshaw as a Vice President and Senior Biotechnology Analyst. He will be covering large- to small-capitalization stocks across a wide therapeutic spectrum. Prior to rejoining Rodman, he was a Healthcare Analyst at Trivium Capital Management. Mr. James first joined Rodman in June 2006, where he worked for two years as Michael King’s Senior Associate. He has also held positions at Daiichi Sankyo as a Manager of New Products and Defined Health as a Pharmaceutical Consultant. He received his medical training in Neurosurgery at the Weill Cornell-New York Hospital. Mr. James holds an MD from Yale School of Medicine and a BS from Cornell University.
About Rodman & Renshaw Capital Group, Inc.
Rodman & Renshaw Capital Group, Inc. is a holding company with a number of direct and indirect subsidiaries, including Rodman & Renshaw, LLC, Rodman Principal Investments, LLC and Miller Mathis & Co., LLC.
Rodman & Renshaw, LLC is a full service investment bank dedicated to providing investment banking services to companies that have significant recurring capital needs due to their growth and development strategies, along with research and sales and trading services to investor clients that focus on such companies. Rodman is a leading investment banking firm with particular emphasis on “essential” industries with significant capital needs, including health care (especially life science), energy (especially upstream oil and gas), ferrous and non-ferrous metals, shipping, and natural resources, as well as a leader in the PIPE (private investment in public equity) and RD (registered direct placements) transaction markets.
MEMBER FINRA, SIPC.
Cautionary Note Regarding Forward Looking Statements
This press release contains forward-looking statements regarding future events and financial performance. In some cases, you can identify these statements by words such as “may,” “might,” “will,” “should,” “expect,” “plan,” “intend,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” or “continue,” the negative of these terms and other comparable terminology. These statements involve a number of risks and uncertainties and are based on numerous assumptions involving judgments with respect to future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the Company’s control. There are or may be important factors that could cause our actual results to materially differ from our historical results or from any future results expressed or implied by such forward looking statements. These factors include, but are not limited to, those discussed under the section entitled “Risk Factors” in our Annual Report on Form 10-K, filed March 14, 2008, which is available at the Securities and Exchange Commission website at www.sec.gov. The forward-looking statements in this press release are based upon management’s reasonable belief as of the date hereof. The Company undertakes no obligation to revise or update publicly any forward-looking statements for any reason.
Source: Business Wire
Popularity: 5% [?]
